



COMPANY OVERVIEW

NeoGenomics, Inc. is a high-complexity CLIA-certified clinical laboratory and pharma services company that specializes in cancer genetics diagnostic testing, the fastest growing segment of the laboratory industry. The company's testing services include cytogenetics, fluorescence in-situ hybridization (FISH), flow cytometry, immunohistochemistry, anatomic pathology, and molecular genetics. Headquartered in Fort Myers, FL, NeoGenomics maintains a network of testing facilities across the US. NeoGenomics services the needs of pathologists, oncologists, urologists and other physician specialists, academic institutions, and the pharmaceutical industry.

NeoGenomics Reports Revenue of \$63.4 Million, Net Income of \$0.6 Million and Adjusted EBITDA of \$9.2 Million in the First Quarter of 2018

May 1 2018, 7:00 AM EDT

NeoGenomics Schedules its First Quarter Earnings Release for May 1, 2018

Apr 2 2018, 5:00 PM EDT

NeoGenomics Announces Executive Appointments

Mar 20 2018, 7:00 AM EDT

STOCK OVERVIEW

Symbol	NEO
Exchange	NASDAQ
Market Cap	914.2m
Last Price	\$11.34
52-Week Range	\$7.08 - \$11.63

INVESTOR RELATIONS

William Bonello
Vice President, Strategy,
Corporate Development and
Investor Relations
T: (239) 690-4238
M: (239) 284-4314
bill.bonello@neogenomics.com

MANAGEMENT TEAM

Douglas M. VanOort

Chairman of the Board of Directors and Chief Executive Officer

Maher Albitar, M.D.

Senior Vice President, Chief Medical Officer and Director of Research and Development

Jennifer Balliet

Vice President and Chief Culture Officer

William Bonello

Vice President, Strategy, Corporate Development and Investor Relations

Steven G. Brodie, Ph.D.

Vice President of Operations

George A. Cardoza

President, Pharma Services Division

Stephanie Bywater

Chief Compliance Officer

Steven C. Jones

Executive Vice President and Board Member

Denise E. Pedulla

General Counsel

Steven A. Ross

Vice President, Chief Information Officer

Robert J. Shovlin

President, Clinical Services Division

Sharon Virag

Chief Financial Officer

NEOGENOMICS, INC.

12701 Commonwealth Dr.
Suite 9
Fort Myers, FL 33913

DISCLAIMER

Except for the historical information contained here in, the matters discussed in this document are forward-looking statements that involve risks and uncertainties, including but not limited to business conditions and the amount of growth in our industry and general economy, competitive factors, and other risks detailed from time to time in the Company's SEC reports, including but not limited to its annual reports on form 10-K and its quarterly reports on Form 10-Q. The company does not undertake any obligation to update forward-looking statements. All trademarks and brand name are the property of their respective companies.